<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18228" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Berylliosis </title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Talati</surname>
            <given-names>Raja</given-names>
          </name>
          <aff>St.Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raja Talati declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18228.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Berylliosis, also known as chronic beryllium disease (CBD), is a granulomatous disease caused by exposure to beryllium. CBD has a variable clinical course with cough, fever, night sweats, and fatigue being the most common symptoms. The definitive diagnosis of berylliosis is based on occupational history, positive blood or bronchoalveolar lavage (BAL) beryllium lymphocyte proliferation test (BeLPT), and granulomatous inflammation on lung biopsy. This activity reviews the evaluation and management of berylliosis and highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of berylliosis.</p></list-item><list-item><p>Explain how to evaluate for berylliosis.</p></list-item><list-item><p>Review treatment strategies for berylliosis.</p></list-item><list-item><p>Employ interprofessional team strategies to improve care coordination and communication to advance care for patients with berylliosis and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18228&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18228">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18228.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Berylliosis, also known as chronic beryllium disease (CBD), is a granulomatous disease caused by exposure to beryllium. CBD has a variable clinical course with&#x000a0;cough, fever, night sweats, and fatigue being the most common symptoms. A definitive&#x000a0;diagnosis of berylliosis&#x000a0;is based&#x000a0;on occupational history, positive blood or bronchoalveolar lavage (BAL) beryllium lymphocyte proliferation test (BeLPT), and granulomatous inflammation on lung biopsy<xref ref-type="bibr" rid="article-18228.r1">[1]</xref>. The current&#x000a0;Occupational Safety and Health Administration (OSHA) guidelines reduce the permissible exposure limit for beryllium to&#x000a0;.2 mcg/m3 averaged over 8 hours or&#x000a0;less&#x000a0;than 2 mcg/m3 over a&#x000a0;15 minute&#x000a0;period.&#x000a0;It is an incurable occupational lung disease, but symptoms can be treated with glucocorticoids and immunosuppressive agents.<xref ref-type="bibr" rid="article-18228.r2">[2]</xref><xref ref-type="bibr" rid="article-18228.r3">[3]</xref><xref ref-type="bibr" rid="article-18228.r4">[4]</xref></p>
        <p>CBD is more likely to develop in individuals who work in industries that manufacture and process beryllium. Overall, there is nothing unique about berylliosis; it is similar to many other granulomatous lung disorders.</p>
      </sec>
      <sec id="article-18228.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Exposure to beryllium is the underlying causative&#x000a0;factor. Heavy beryllium-using industries include metal machine shops, electronics, defense industries, and beryllium extraction companies. Other industries include ceramic, automotive, aerospace, jewelry&#x000a0;making, dental/alloy appliance, and computer.&#x000a0;It&#x000a0;appears that some people may have a genetic predisposition towards developing severe CBD.<xref ref-type="bibr" rid="article-18228.r5">[5]</xref></p>
        <p>Beryllium exposure tends to occur via inhalation of beryllium fumes or dust, but it can also be absorbed following skin exposure. The organic forms of beryllium are rapidly excreted, but the insoluble inorganic particles can remain in the body for many years.</p>
      </sec>
      <sec id="article-18228.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>CBD is a hypersensitivity granulomatous disease that occurs in 2 to 5% of beryllium-exposed workers<xref ref-type="bibr" rid="article-18228.r6">[6]</xref>. Stopping exposure to beryllium has not been shown to stop the progression to CBD. Unless an individual lives very&#x000a0;close to an industrial site, the general population is unlikely to develop acute or CBD because ambient air levels of beryllium are normally very&#x000a0;low (&#x0003c; 0.03 ng/m3)<xref ref-type="bibr" rid="article-18228.r5">[5]</xref>.</p>
      </sec>
      <sec id="article-18228.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Exposure to beryllium can lead to a cell-mediated immune response where T-cells become sensitized to beryllium. Each subsequent exposure leads to an immune response involving macrophages and CD4+ helper T-lymphocytes accumulating in the lungs. As this response proceeds, macrophages, CD+4 T-lymphocytes, and plasma cells aggregate to form noncaseating granulomas that evolve&#x000a0;to cause fibrosis of the lung. Studies have revealed there is a genetic component to beryllium sensitivity. Specifically, those beryllium-exposed workers with a mutation at the HLA-DPB1 Glu69 position have increased the prevalence of beryllium sensitization and CBD. The HLA-DPB1 gene is important for MCH class II molecule function on antigen-presenting cells. Beryllium and beryllium compounds are category 1 carcinogens and&#x000a0;carcinogenic to both animals and humans.<xref ref-type="bibr" rid="article-18228.r7">[7]</xref></p>
      </sec>
      <sec id="article-18228.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The key feature on histopathology is the nonnecrotizing granulomas in the lung; which mimic those seen in sarcoidosis.</p>
      </sec>
      <sec id="article-18228.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical manifestations of CBD are nonspecific<xref ref-type="bibr" rid="article-18228.r8">[8]</xref>. The latency period between beryllium exposure and the onset of symptoms varies from three months to 30 years<xref ref-type="bibr" rid="article-18228.r9">[9]</xref>.&#x000a0;Common symptoms include fever, night sweats, weight loss, dry cough, and fatigue. Continued exposure causes&#x000a0;noncaseating inflammatory granulomas.&#x000a0;They also see granulomas&#x000a0;in other chronic diseases, such as tuberculosis and sarcoidosis. CBD leads to restrictive lung disease (a decrease in diffusion capacity). Rarely, granulomas&#x000a0;occur in other organs, such as the liver.&#x000a0;</p>
        <p>The physical exam may reveal lymphadenopathy, crackles, rash, and hepatosplenomegaly.</p>
      </sec>
      <sec id="article-18228.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A definitive diagnosis of berylliosis is based on the history, positive blood or bronchoalveolar lavage (BAL) beryllium lymphocyte proliferation test (BeLPT), and granulomatous inflammation on lung biopsy<xref ref-type="bibr" rid="article-18228.r1">[1]</xref>. Establishing beryllium sensitivity is the first step, and this is determined by the beryllium lymphocyte proliferation test (BeLPT). The test is performed by acquiring either peripheral blood or fluid from a bronchial alveolar lavage and&#x000a0;culturing&#x000a0;lymphocytes with beryllium sulfate. Cells are then counted, and they consider those with an elevated number of cells abnormal. Those exposed persons with two abnormal BeLPTs with peripheral blood or one abnormal and one borderline result are beryllium sensitized. Also, those with one abnormal BeLPT with fluid from a bronchial alveolar lavage is&#x000a0;considered sensitized. For patients with positive BeLPT, bronchoscopy with bronchoalveolar lavage (BAL) is performed to obtain cell counts<xref ref-type="bibr" rid="article-18228.r1">[1]</xref>. Lastly, a tissue biopsy is obtained from bronchoscopy to fulfill the last criterion for CBD diagnosis.&#x000a0;<xref ref-type="bibr" rid="article-18228.r10">[10]</xref></p>
        <p>Chest radiography findings of berylliosis are non-specific. Early in the disease, radiography findings are usually normal. In later stages, interstitial fibrosis, pleural irregularities, hilar lymphadenopathy, and ground-glass opacities have been reported. Findings on CT are not specific for berylliosis. Findings that are&#x000a0;common in CT scans of people with berylliosis include parenchymal nodules in early stages. One study found that ground-glass opacities were more commonly seen on CT scan in berylliosis than in sarcoidosis. In later stages, hilar lymphadenopathy, interstitial pulmonary fibrosis, and pleural thickening are found.</p>
        <p>Other tests include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Arterial blood gas</p>
          </list-item>
          <list-item>
            <p>Pulmonary function tests</p>
          </list-item>
          <list-item>
            <p>Spirometry</p>
          </list-item>
          <list-item>
            <p>DLCO levels</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18228.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The&#x000a0;goals when treating berylliosis are to reduce symptoms and slow the progression of the&#x000a0;disease as no cure is available. Although there is no evidence that stopping exposure to beryllium decreases the progression of the disease, they still consider it to be an accepted approach to treatment. People with early stages, without lung function abnormalities or clinical symptoms, are periodically monitored, with physical exams, pulmonary function tests, and radiography. All patients require&#x000a0;influenza and pneumococcal&#x000a0;vaccination and smoking cessation counseling. After the appearance of clinical symptoms or significant abnormalities appears&#x000a0;in pulmonary function testing, oxygen and oral corticosteroids are started as well as other supportive therapy as required.<xref ref-type="bibr" rid="article-18228.r1">[1]</xref>&#x000a0;</p>
        <p>The drugs of choice to treat chronic beryllium disease are corticosteroids. It usually requires a high starting dose and the treatment duration is often for several months before they see symptom resolution. Once symptoms subside, tapering of the steroids is necessary to prevent the adverse effects. Patients who fail to respond to steroids&#x000a0;are started on immunosuppressive agents such as methotrexate and azathioprine. Oral methotrexate at a 7.5mg weekly dose is given with folic acid 1 mg. Complete blood counts and liver function tests should be repeated 8 to 12 weeks at a time.</p>
        <p>Once a diagnosis of CBD is made, the patient needs life-long follow up with serial arterial blood gases, chest x-ray, and pulmonary function tests.<xref ref-type="bibr" rid="article-18228.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18228.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis includes sarcoidosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, asthma, and other granulomatous lung diseases such as histoplasmosis, tuberculosis, silicosis. It is estimated that 6 percent of all patients diagnosed with sarcoidosis may have CBD<xref ref-type="bibr" rid="article-18228.r12">[12]</xref>.</p>
      </sec>
      <sec id="article-18228.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with beryllium sensitization in the absence of CBD do not require treatment but should undergo periodic evaluation.&#x000a0;Among these patients, the risk of progression to CBD is increased compared with non-sensitized workers.&#x000a0;Overall mortality rates are 5% to 38%<xref ref-type="bibr" rid="article-18228.r13">[13]</xref>. CBD has a variable clinical course. A higher percentage of lymphocytes in the bronchoalveolar lavage correlates with greater severity of illness<xref ref-type="bibr" rid="article-18228.r14">[14]</xref>. Disability is common in people with preexisting lung disease and smokers. The granulomas lead to nodule formation, which can impair lung function.</p>
      </sec>
      <sec id="article-18228.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Prevention is the key in the management of berylliosis. OSHA has recommendations for the workplace including requiring work practice controls such as ventilation or enclosure to limit exposure, provide protective equipment such as respirators, train workers on beryllium hazards, and requiring medical exams to monitor exposed workers. In 2000, a study found that new workers who went through a comprehensive preventive program had reduced beryllium sensitization compared with workers working in the past<xref ref-type="bibr" rid="article-18228.r15">[15]</xref>.</p>
      </sec>
      <sec id="article-18228.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A study of workers in a beryllium facility found that people developed CBD when exposed to above&#x000a0;0.2 mcg/m3<xref ref-type="bibr" rid="article-18228.r16">[16]</xref>. The current United States Occupational Safety and Health Administration (OSHA) reduces the permissible exposure limit for beryllium to&#x000a0;0.2 mcg/m3 averaged over 8 hours or less than 2 mcg/m3 over a 15 minute period.</p>
        <p>The American Conference of Governmental Industrial Hygienists (ACGIH) in 2005 issued a recommendation to reduce the threshold limit value (TLV) by 100 fold from 2 to&#x000a0;0.02 mcg/m3 over a 15 minute period. Although ACGIH carries no legal force&#x000a0;as OSHA does, it is important to note the recommendation. Beryllium exposure is difficult to control in an industrial work environment, so methods that&#x000a0;reduce the possibility of airborne and surface contamination are needed. These include minimal use of beryllium and beryllium-containing alloys and employee education about the possible hazards when the dust or fumes of beryllium are encountered in the workplace.</p>
      </sec>
      <sec id="article-18228.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Several guidelines have been developed&#x000a0;to help prevent berylliosis in the workplace. However, an interprofessional approach is required to ensure that the diagnosis is not missed. Patients often present to the primary health care provider who may not be aware of the disorder, hence referral&#x000a0;to a pulmonologist is recommended. The pharmacist should advise the patient to discontinue smoking, and the nurse should educate the patient and the family on the disease. A pulmonologist may help make the diagnosis and help monitor the disease. In industries that handle beryllium, the public health nurse should create awareness of the disorder and how to prevent it. Workers should be told to wear a mask and appropriate long-sleeved garments. Some industries also refer the workers for annual chest exams. Patients should be told to quit smoking and change occupation if the exposure is high. The pharmacist should discuss the potential side effects of steroids, and monitor the patient for complications, reporting to the healthcare team.&#x000a0;<xref ref-type="bibr" rid="article-18228.r17">[17]</xref>[Level V]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>In the USA, berylliosis is declining, but outside North America,&#x000a0;it is still a problem because of unregulated textile industries. A detailed work exposure, history, physical examination, radiography, pulmonary function test, selected lab studies, and bronchoalveolar lavage fluid can be used&#x000a0;to&#x000a0;identify early stages of disease. <xref ref-type="bibr" rid="article-18228.r18">[18]</xref> [Level V]</p>
      </sec>
      <sec id="article-18228.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18228&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18228">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/berylliosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18228">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18228/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18228">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18228.s16">
        <title>References</title>
        <ref id="article-18228.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balmes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dweik</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Fireman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fontenot</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Muller-Quernheim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ostiguy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Saltini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Takaro</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Wambach</surname>
                <given-names>PF</given-names>
              </name>
              <collab>ATS Ad Hoc Committee on Beryllium Sensitivity and Chronic Beryllium Disease</collab>
            </person-group>
            <article-title>An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>190</volume>
            <issue>10</issue>
            <fpage>e34</fpage>
            <page-range>e34-59</page-range>
            <pub-id pub-id-type="pmid">25398119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fordyce</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>A mortality study of beryllium workers.</article-title>
            <source>Cancer Med</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>3596</fpage>
            <page-range>3596-3605</page-range>
            <pub-id pub-id-type="pmid">27766788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <collab>Occupational Safety and Health Administration (OSHA), Department of Labor</collab>
            <article-title>Occupational Exposure to Beryllium. Final rule.</article-title>
            <source>Fed Regist</source>
            <year>2017</year>
            <month>Jan</month>
            <day>09</day>
            <volume>82</volume>
            <issue>5</issue>
            <fpage>2470</fpage>
            <page-range>2470-757</page-range>
            <pub-id pub-id-type="pmid">28071878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fechter-Leggett</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>McCanlies</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease.</article-title>
            <source>J Occup Environ Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>855</fpage>
            <page-range>855-60</page-range>
            <pub-id pub-id-type="pmid">27414009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamzeh</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Beryllium and other metal-induced lung disease.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-84</page-range>
            <pub-id pub-id-type="pmid">25602804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Zhen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martyny</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of beryllium sensitization and disease in nuclear workers.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>148</volume>
            <issue>4 Pt 1</issue>
            <fpage>985</fpage>
            <page-range>985-91</page-range>
            <pub-id pub-id-type="pmid">8214955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hamzeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fingerlin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.</article-title>
            <source>Eur Respir J</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>1797</fpage>
            <page-range>1797-808</page-range>
            <pub-id pub-id-type="pmid">27103383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoeckle</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature.</article-title>
            <source>Am J Med</source>
            <year>1969</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>545</fpage>
            <page-range>545-61</page-range>
            <pub-id pub-id-type="pmid">4892951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelleher</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Martyny</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ruttenber</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Beryllium particulate exposure and disease relations in a beryllium machining plant.</article-title>
            <source>J Occup Environ Med</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-49</page-range>
            <pub-id pub-id-type="pmid">11285872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alongi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Beryllium BioBank: 2. Lymphocyte proliferation testing.</article-title>
            <source>J Occup Environ Med</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>8</issue>
            <fpage>857</fpage>
            <page-range>857-60</page-range>
            <pub-id pub-id-type="pmid">25099413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Deubner</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy of a program to prevent beryllium disease.</article-title>
            <source>Am J Ind Med</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>733</fpage>
            <page-range>733-41</page-range>
            <pub-id pub-id-type="pmid">23450749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fireman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haimsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Noiderfer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Priel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lerman</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Misdiagnosis of sarcoidosis in patients with chronic beryllium disease.</article-title>
            <source>Sarcoidosis Vasc Diffuse Lung Dis</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-8</page-range>
            <pub-id pub-id-type="pmid">12870725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daniloff</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The natural history of beryllium sensitization and chronic beryllium disease.</article-title>
            <source>Environ Health Perspect</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>104 Suppl 5</volume>
            <issue>Suppl 5</issue>
            <fpage>937</fpage>
            <page-range>937-43</page-range>
            <pub-id pub-id-type="pmid">8933038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Bobka</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Daniloff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Compartmentalized immune response reflects clinical severity of beryllium disease.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>150</volume>
            <issue>1</issue>
            <fpage>135</fpage>
            <page-range>135-42</page-range>
            <pub-id pub-id-type="pmid">8025739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Deubner</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Henneberger</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Kitt</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers.</article-title>
            <source>Occup Environ Med</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-40</page-range>
            <pub-id pub-id-type="pmid">17043076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madl</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Unice</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kolanz</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant.</article-title>
            <source>J Occup Environ Hyg</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>448</fpage>
            <page-range>448-66</page-range>
            <pub-id pub-id-type="pmid">17474035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chiyotani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>De Vuyst</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dumortier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Hosoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kohyama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ostiguy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roggli</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Shida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vallyathan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Proposed criteria for mixed-dust pneumoconiosis: definition, descriptions, and guidelines for pathologic diagnosis and clinical correlation.</article-title>
            <source>Hum Pathol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1515</fpage>
            <page-range>1515-23</page-range>
            <pub-id pub-id-type="pmid">15619211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18228.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zacharisen</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity pneumonitis and related conditions in the work environment.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>769</fpage>
            <page-range>769-86, vii</page-range>
            <pub-id pub-id-type="pmid">21978856</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
